Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
7773 | 1329 | 37.0 | 76% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
103 | 3 | O GLCNACYLATION//O GLCNAC TRANSFERASE//O GLCNACASE | 73436 |
1273 | 2 | GANGLIOSIDES//SIALIC ACID//GLYCOSPHINGOLIPIDS | 8760 |
7773 | 1 | GANGLIOSIDES//GD2//CH1418 | 1329 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | GANGLIOSIDES | authKW | 360087 | 14% | 8% | 187 |
2 | GD2 | authKW | 290486 | 2% | 45% | 28 |
3 | CH1418 | authKW | 206771 | 1% | 100% | 9 |
4 | N GLYCOLYLNEURAMINIC ACID | authKW | 161003 | 2% | 26% | 27 |
5 | GLYCOIMMUNOTHER Y | address | 153157 | 1% | 67% | 10 |
6 | GD2 GANGLIOSIDE | authKW | 132918 | 1% | 64% | 9 |
7 | NEUGCGM3 | authKW | 114873 | 0% | 100% | 5 |
8 | GANGLIOSIDE SHEDDING | authKW | 103382 | 0% | 75% | 6 |
9 | ANTI GD2 | authKW | 102336 | 1% | 64% | 7 |
10 | GANGLIOSIDE GD2 | authKW | 102336 | 1% | 64% | 7 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Oncology | 7170 | 39% | 0% | 512 |
2 | Immunology | 4133 | 28% | 0% | 367 |
3 | Biochemistry & Molecular Biology | 899 | 25% | 0% | 330 |
4 | Medicine, Research & Experimental | 443 | 8% | 0% | 105 |
5 | Biophysics | 176 | 5% | 0% | 70 |
6 | Cell Biology | 126 | 7% | 0% | 94 |
7 | Biochemical Research Methods | 109 | 4% | 0% | 53 |
8 | Hematology | 67 | 3% | 0% | 40 |
9 | Biotechnology & Applied Microbiology | 52 | 4% | 0% | 56 |
10 | Allergy | 36 | 1% | 0% | 13 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | GLYCOIMMUNOTHER Y | 153157 | 1% | 67% | 10 |
2 | CANC TRANSPLANTAT BIOL | 93037 | 1% | 45% | 9 |
3 | TUMOR GLYCOBIOL | 59071 | 0% | 43% | 6 |
4 | GLYCOBIOL TRAINING | 53692 | 2% | 9% | 26 |
5 | INT EPIDEM | 45949 | 0% | 100% | 2 |
6 | RECOGNIT BIOL ACT ASSAYS | 45949 | 0% | 100% | 2 |
7 | ANTIBODY ENGN | 30698 | 2% | 7% | 20 |
8 | TUMOR IMMUNOL DIRECT | 29535 | 0% | 43% | 3 |
9 | AHAB PHATTNA | 22975 | 0% | 100% | 1 |
10 | ANESTHESIOL ANESTHESIOL S | 22975 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | CANCER IMMUNOLOGY IMMUNOTHERAPY | 13169 | 4% | 1% | 50 |
2 | CANCER RESEARCH | 5673 | 7% | 0% | 99 |
3 | GLYCOCONJUGATE JOURNAL | 5624 | 2% | 1% | 22 |
4 | HYBRIDOMA | 5259 | 2% | 1% | 22 |
5 | JOURNAL OF IMMUNOTHERAPY | 3919 | 1% | 1% | 17 |
6 | HYBRIDOMA AND HYBRIDOMICS | 3364 | 0% | 2% | 6 |
7 | INTERNATIONAL JOURNAL OF CANCER | 1856 | 3% | 0% | 41 |
8 | CLINICAL CANCER RESEARCH | 1536 | 2% | 0% | 32 |
9 | JAPANESE JOURNAL OF CANCER RESEARCH | 1433 | 1% | 0% | 15 |
10 | JOURNAL OF BIOCHEMISTRY | 1406 | 2% | 0% | 26 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | GANGLIOSIDES | 360087 | 14% | 8% | 187 | Search GANGLIOSIDES | Search GANGLIOSIDES |
2 | GD2 | 290486 | 2% | 45% | 28 | Search GD2 | Search GD2 |
3 | CH1418 | 206771 | 1% | 100% | 9 | Search CH1418 | Search CH1418 |
4 | N GLYCOLYLNEURAMINIC ACID | 161003 | 2% | 26% | 27 | Search N+GLYCOLYLNEURAMINIC+ACID | Search N+GLYCOLYLNEURAMINIC+ACID |
5 | GD2 GANGLIOSIDE | 132918 | 1% | 64% | 9 | Search GD2+GANGLIOSIDE | Search GD2+GANGLIOSIDE |
6 | NEUGCGM3 | 114873 | 0% | 100% | 5 | Search NEUGCGM3 | Search NEUGCGM3 |
7 | GANGLIOSIDE SHEDDING | 103382 | 0% | 75% | 6 | Search GANGLIOSIDE+SHEDDING | Search GANGLIOSIDE+SHEDDING |
8 | ANTI GD2 | 102336 | 1% | 64% | 7 | Search ANTI+GD2 | Search ANTI+GD2 |
9 | GANGLIOSIDE GD2 | 102336 | 1% | 64% | 7 | Search GANGLIOSIDE+GD2 | Search GANGLIOSIDE+GD2 |
10 | ANTI GD2 MONOCLONAL ANTIBODY | 91898 | 0% | 100% | 4 | Search ANTI+GD2+MONOCLONAL+ANTIBODY | Search ANTI+GD2+MONOCLONAL+ANTIBODY |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | SUZUKI, M , CHEUNG, NKV , (2015) DISIALOGANGLIOSIDE GD2 AS A THERAPEUTIC TARGET FOR HUMAN DISEASES.EXPERT OPINION ON THERAPEUTIC TARGETS. VOL. 19. ISSUE 3. P. 349 -362 | 70 | 58% | 17 |
2 | HORTA, ZP , GOLDBERG, JL , SONDEL, PM , (2016) ANTI-GD2 MABS AND NEXT-GENERATION MAB-BASED AGENTS FOR CANCER THERAPY.IMMUNOTHERAPY. VOL. 8. ISSUE 9. P. 1097 -1117 | 80 | 55% | 1 |
3 | RABU, C , MCINTOSH, R , JURASOVA, Z , DURRANT, L , (2012) GLYCANS AS TARGETS FOR THERAPEUTIC ANTITUMOR ANTIBODIES.FUTURE ONCOLOGY. VOL. 8. ISSUE 8. P. 943 -960 | 78 | 56% | 12 |
4 | CASADESUS, AV , FERNANDEZ-MARRERO, Y , CLAVELL, M , GOMEZ, JA , HERNANDEZ, T , MORENO, E , LOPEZ-REQUENA, A , (2013) A SHIFT FROM N-GLYCOLYL- TO N-ACETYL-SIALIC ACID IN THE GM3 GANGLIOSIDE IMPAIRS TUMOR DEVELOPMENT IN MOUSE LYMPHOCYTIC LEUKEMIA CELLS.GLYCOCONJUGATE JOURNAL. VOL. 30. ISSUE 7. P. 687-699 | 50 | 68% | 6 |
5 | AHMED, M , CHEUNG, NKV , (2014) ENGINEERING ANTI-GD2 MONOCLONAL ANTIBODIES FOR CANCER IMMUNOTHERAPY.FEBS LETTERS. VOL. 588. ISSUE 2. P. 288-297 | 54 | 49% | 24 |
6 | AMON, R , REUVEN, EM , BEN-ARYE, SL , PADLER-KARAVANI, V , (2014) GLYCANS IN IMMUNE RECOGNITION AND RESPONSE.CARBOHYDRATE RESEARCH. VOL. 389. ISSUE . P. 115-122 | 61 | 43% | 19 |
7 | MALYKH, YN , SCHAUER, R , SHAW, L , (2001) N-GLYCOLYLNEURAMINIC ACID IN HUMAN TUMOURS.BIOCHIMIE. VOL. 83. ISSUE 7. P. 623 -634 | 54 | 65% | 146 |
8 | NAVID, F , SANTANA, VM , BARFIELD, RC , (2010) ANTI-GD2 ANTIBODY THERAPY FOR GD2-EXPRESSING TUMORS.CURRENT CANCER DRUG TARGETS. VOL. 10. ISSUE 2. P. 200-209 | 41 | 64% | 45 |
9 | CHEUNG, NKV , DOBRENKOV, K , (2014) GD2-TARGETED IMMUNOTHERAPY AND RADIOIMMUNOTHERAPY.SEMINARS IN ONCOLOGY. VOL. 41. ISSUE 5. P. 589 -612 | 52 | 46% | 8 |
10 | SHUSTERMAN, S , LONDON, WB , GILLIES, SD , HANK, JA , VOSS, SD , SEEGER, RC , REYNOLDS, CP , KIMBALL, J , ALBERTINI, MR , WAGNER, B , ET AL (2010) ANTITUMOR ACTIVITY OF HU14.18-IL2 IN PATIENTS WITH RELAPSED/REFRACTORY NEUROBLASTOMA: A CHILDREN'S ONCOLOGY GROUP (COG) PHASE II STUDY.JOURNAL OF CLINICAL ONCOLOGY. VOL. 28. ISSUE 33. P. 4969-4975 | 30 | 77% | 56 |
Classes with closest relation at Level 1 |